The U.S. Food and Drug Administration (FDA) has issued a partial clinical hold in response to an application by Yumanity Therapeutics requesting permission to begin clinical testing in the U.S. of YTX-7739 for Parkinson’s disease. With this decision, the FDA is allowing Yumanity to conduct a planned clinical…
The protein alpha-synuclein, which has a well-established role in the development of Parkinson’s disease, is necessary for the body to mount a normal immune response against infections. “This study provides further evidence that αS [alpha-synuclein], the protein intimately linked with the pathogenesis of PD [Parkinson’s disease], is a critical…
Green Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in people with early-stage Parkinson’s disease, according to a press release. This follows the acceptance of Green Valley‘s investigational new drug (IND) application by the U.S Food and Drug…
A team of scientists at the University of Cincinnati, in Ohio, has received a grant worth $1.2 million from the U.S. Department of Defense (DOD) to study how stress can affect — and worsen the progression of — Parkinson’s disease. The researchers, led by Kim Seroogy, PhD, previously showed…
The Michael J. Fox Foundation has awarded $5.2 million to scientists at Arizona State University (ASU) to support three research projects exploring new treatment options for Parkinson’s disease. The projects will be led by Jeffrey Kordower, PhD, founding director of the Banner Neurodegenerative Disease Research Center at ASU.
ABL Bio and Sanofi are working under a global licensing agreement to jointly develop ABL301 — an investigational bispecific antibody targeting both alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) — in possibly treating Parkinson’s disease. Under the agreement, ABL Bio will lead further preclinical testing and a…
Zhittya Genesis Medicine plans to launch what it is calling a “Compassionate Use Clinical Trial” of FGF-1, a biological compound aiming to stimulate new blood vessel growth in the brain, for people with mild-to-moderately severe Parkinson’s disease. Those interested in joining this open-label (no placebo group) pilot safety and early efficacy…
People who took part in remote, video-conducted clinical trials for Parkinson’s disease reported high levels of satisfaction and interest in participating in future studies with remote video visits, scientists report. Three such trials showed that recruitment was feasible and enrolled participants were geographically dispersed — from across dozens of…
A first patient with Parkinson’s disease has been dosed with UB-312, Vaxxinity’s experimental vaccine therapy targeting alpha-synuclein, after treatment safety and tolerability was seen in healthy volunteers in a clinical trial. This marks the beginning of Part B in the Phase 1 trial (NCT04075318), which is enrolling up…
Yumanity Therapeutics has been awarded a $500,000 research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help accelerate testing of an investigational Parkinson’s disease therapy, YTX-7739. “MJFF is a globally recognized advocate and supporter of innovative research toward new treatments to stop Parkinson’s…
Get regular updates to your inbox.